Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan

  1. Cesheng Li
  2. Ding Yu
  3. Xiao Wu
  4. Hong Liang
  5. Zhijun Zhou
  6. Yong Xie
  7. Taojing Li
  8. Junzheng Wu
  9. Fengping Lu
  10. Lu Feng
  11. Min Mao
  12. Lianzhen Lin
  13. Huanhuan Guo
  14. Shenglan Yue
  15. Feifei Wang
  16. Yan Peng
  17. Yong Hu
  18. Zejun Wang
  19. Jianhong Yu
  20. Yong Zhang
  21. Jia Lu
  22. Haoran Ning
  23. Huichuan Yang
  24. Daoxing Fu
  25. Yanlin He
  26. Dongbo Zhou
  27. Tao Du
  28. Kai Duan
  29. Demei Dong
  30. Kun Deng
  31. Xia Zou
  32. Ya Zhang
  33. Rong Zhou
  34. Yang Gao
  35. Xinxin Zhang
  36. Xiaoming Yang

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 35.7% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.

Article activity feed

  1. Version published to 10.1038/s41467-021-24230-5
  2. Version published to 10.1101/2021.04.05.437224v2 on bioRxiv
  3. ScreenIT

    SciScore for 10.1101/2021.04.05.437224: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Detection of SARS-CoV-2 RBD-IgG: CE-marked coronavirus IgG antibody detection kit (batch number: NCOG20200808B) from Beijing WanTai Biological Pharmacy Enterprise Co., Ltd. (Beijing, China) was used to test the titer of RBD-IgG.
    SARS-CoV-2 RBD-IgG: CE-marked coronavirus IgG antibody detection kit
    suggested: None
    CE-marked coronavirus IgG
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Plaque reduction neutralization test (PRNT): Neutralizing titers were defined on Vero cells by PRNT.
    Vero
    suggested: CLS Cat# 605372/p622_VERO, RRID:CVCL_0059)
    The serum-virus mixture was added into pre-cultured Vero E6 cell monolayers for 1-h incubation at 37°C under 5% CO2.
    Vero E6
    suggested: None
    Experimental Models: Organisms/Strains
    SentencesResources
    The proportion of plasma Rh-positive blood types (a total of 834 donors with blood type recorded) of A, B, O, and AB was 34.89%, 27.46%, 29.38%, and 8.27%, respectively (Figure 6B).
    AB
    suggested: None
    Software and Algorithms
    SentencesResources
    Statistical analyses: GraphPad Prism 9.0 was used for statistical analysis.
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  4. Version published to 10.1101/2021.04.05.437224v1 on bioRxiv